Pfizer, BioNTech Say Omicron Shot Offers More Protection Than Original Vax

By Lia DeGroot / November 4, 2022 at 6:40 PM

Updated phase 2/3 trial data from Pfizer and BioNTech show that adults who received the companies’ bivalent booster had four times higher protection against the Omicron variant and its sublineages than they did after receiving the original COVID-19 vaccine booster, Pfizer and BioNTech announced Friday (Nov. 4).

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.

FEATURES

NEWSLETTERS

ABOUT US

Inside Health Policy is a subscription-fee-based daily digital news service from Inside Washington Publishers.

SITE LICENSES

Economical site license packages are available to fit any size organization, from a few people at one location to company-wide access. For more information on how you can get greater access to Inside Health Policy for your office, contact Online Customer Service at 703-416-8505 or healthpolicy@iwpnews.com.

STAY CONNECTED

Pfizer, BioNTech Say Omicron Shot Offers More Protection Than Original Vax

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.